profit from every $100 of sales.
$0$100
Precision BioSciences
$7.57-5.91% today
+29.3% in 1 year
1-year low $3.571-year high $10.60
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Precision BioSciences sold, what it kept, and what it did with the cash.
Sales went from $25.1 million in 2022 to $34.3 million in 2025, with -$45.7 million of profit last year.
SalesProfit
Precision BioSciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Precision BioSciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Precision BioSciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 25 | 49 | 69 | 34 | |
| – | – | – | – | |
| -62 | -44 | -26 | -52 | |
| -63 | -32 | 14 | -42 | |
| -112 | -61 | 7 | -46 | |
| -38.10 | -15.96 | 1.04 | -3.56 | |
| – | – | – | – | |
| -248.3% | -89.8% | -38.1% | -152.2% | |
| -444.8% | -125.8% | 10.4% | -133.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 238 | 160 | 136 | 154 |
| Cash | 190 | 117 | 86 | 111 |
| Total debt | 25 | 31 | 30 | 29 |
| Total liabilities | 178 | 141 | 80 | 62 |
| 60 | 19 | 56 | 92 | |
| 3 | 4 | 7 | 13 | |
| -66.4% | -63.5% | 8.2% | -29.5% | |
| -184.7% | -325.1% | 12.7% | -49.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -46 | -84 | -58 | -66 | |
| 3 | 2 | 0 | 1 | |
| -49 | -86 | -59 | -67 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 19 | 14 | 13 | 10 |
Valuation
- –
- –
- –
- 1.2×
- 8.4×
- –
- –
- -23.0%
- -15.8%
- 0.0%
Profitability
- 97.0%
- -152.2%
- -133.4%
- -69.6%
- -28.4%
- -62.8%
- -81.2%
- -30.9%
- -28.7%
- 118.4%
Growth
- +10.9%
- –
- −12.3%
- –
- +60.0%
Financial health
- -1.9×
- 0.37
- 19.8%
- -28.4×
- 14.02
- 14.02
- 0.31
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 17%of 946
Bottom 2%of 871
Bottom 48%of 867
Bottom 4%of 986
What analysts expect
- Average price target
- $19.00
- Range
- $19.00 – $19.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.34 | -0.27 | −25.9% |
| Mar 12, 2026 | 0.36 | -0.21 | +271.4% |
| Nov 3, 2025 | -1.84 | -0.31 | −493.5% |
| Aug 7, 2025 | -2.13 | -0.09 | −2,266.7% |
| May 15, 2025 | -2.21 | -0.43 | −414.0% |
| Mar 26, 2025 | -3.20 | -2.09 | −53.1% |
| Nov 4, 2024 | -2.83 | -0.79 | −258.2% |
| Aug 1, 2024 | 3.46 | -0.77 | +549.4% |
News
Global Clinical Genomics Software Market Report 2026 | Capitalize on 14.8% CAGR Through 2030 as Google, Microsoft, NVIDIA and Illumina Scale AI, Cloud and Precision MedicineYahoo Finance · Nov 9, 2026Global Clinical Knowledge Graphs for Genomics Market Report 2026 | Capitalize on 20.7% CAGR as Microsoft, IBM, Illumina and Genomenon Scale AI, Cloud and Precision MedicineYahoo Finance · Oct 30, 2026Precision Drilling GAAP EPS of C$1.65 misses by C$0.45, revenue of C$531.65M beats by C$1.94MSeeking Alpha · Oct 28, 2026Catheter Precision to rebrand as Flyte Aviation, adopt VJET tickerSeeking Alpha · Oct 2, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
64Pass
Philip Fisher
44No pass
Peter Lynch
46No pass
Joel Greenblatt
2No pass
Charlie Munger
40No pass
Terry Smith
49No pass
Questions about Precision BioSciences
Is Precision BioSciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Precision BioSciences AI analysis
What does Precision BioSciences do?
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. It is in Biotechnology.
Does Precision BioSciences pay a dividend?
No. Precision BioSciences does not pay a dividend at the moment.
Is Precision BioSciences stock halal?
No. Precision BioSciences does not pass our halal screen: its cash and confirmed interest-bearing investments are 38% of its market value, at or above the 33% limit. How we check
How has Precision BioSciences stock done over the past year?
Up 29.3% over the past twelve months, to $7.57. It traded between $3.57 and $10.60 and is 28.6% below its high.
Who are Precision BioSciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Precision BioSciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.